靶向RAS：超越KRASG12C
Drugging RAS: Moving Beyond KRASG12C.
出版信息
Cancer Discov. 2023 Dec 12;13(12):OF7. doi: 10.1158/2159-8290.CD-ND2023-0010.
Abstract
Preliminary results from phase I trials respectively evaluating RMC-6236, a pan-RAS inhibitor, and HRS-4642, a KRASG12D inhibitor, indicate that both are safe and show promising signs of antitumor activity. These are just two of the candidate RAS therapies in a burgeoning development space as the field looks ahead to drugs that hit more than just KRASG12C.
摘要
分别评估泛RAS抑制剂RMC-6236和KRAS G12D抑制剂HRS-4642的I期试验初步结果表明，二者均安全且显示出有前景的抗肿瘤活性迹象。随着该领域期待开发出不仅作用于KRAS G12C的药物，在这个蓬勃发展的领域中，这只是两种候选RAS疗法。
Zotero 插件